Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 3Gynecologic 2Genitourinary 2Dermatologic 2Breast 2

Conditions

Pancreatic Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Neoplasms 1

Interventions

Oxaliplatin 1435Fluorouracil 1316Capecitabine 1112Gemcitabine 1054Leucovorin 935Bevacizumab 845Irinotecan 827Cisplatin 673Radiotherapy 559Cetuximab 481pembrolizumab 435Paclitaxel 400Drug Therapy 358Nivolumab 349130-nm albumin-bound paclitaxel 326Docetaxel 289Sorafenib 288S 1 (combination) 278Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 256lenvatinib 222sintilimab 218tislelizumab 213durvalumab 211regorafenib 208Radiosurgery 204Magnetic Resonance Spectroscopy 203apatinib 202Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
AM0010 × Gastrointestinal × Clear all
NCT02009449 2024-11-15

IVY

Eli Lilly and Company

Phase 1 Completed
353 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02923921 2020-10-19

Sequoia

Eli Lilly and Company

Phase 3 Completed
567 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡